secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001493152-26-012807
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded
-----------------------------------------------------------------------------

- Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).
- Cash $34.7M at Dec 31, 2025 vs $22.4M at Dec 31, 2024; operating expenses $15.5M incl $1.2M stock-based comp.
- Awarded U.S. Department of Veterans Affairs contract for EsoGuard with $1,938 Medicare-aligned pricing across 170 VA medical centers.
- Largest real-world esophageal precancer detection study (nearly 12,000 patients) shows EsoCheck 95% technical success rate and 95% procedures under two minutes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/0001493152-26-012807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315226012807/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer